NC-MEDICAGO
12.3.2020 12:32:09 CET | Business Wire | Press release
Medicago, a biopharmaceutical company headquartered in Quebec City, announced today that they have successfully produced a Virus-Like Particle (VLP) of the coronavirus just 20 days after obtaining the SARS-CoV-2 (virus causing the COVID-19 disease) gene. Production of the VLP is the first step in developing a vaccine for COVID-19, which will now undergo preclinical testing for safety and efficacy. Once this is completed, Medicago expects to discuss with the appropriate Health Agencies to initiate human trials of the vaccine by summer (July/August) 2020.
Medicago is also using its technology platform to develop antibodies against SARS-CoV-2 in collaboration with the Laval University’s Infectious Disease Research Centre headed by Dr. Gary Kobinger, who helped develop a vaccine and treatment for Ebola. These SARS-CoV-2 antibodies could potentially be used to treat people infected by the virus. This research is being funded, in part, by the Canadian Institutes for Health Research (CIHR).
Medicago is a leader in plant-based technology, having previously demonstrated its capability to be a first responder in a flu pandemic. In 2009, the company produced a research-grade vaccine candidate against H1N1 in just 19 days. In 2012, Medicago manufactured 10 million doses of a monovalent influenza vaccine within one month for the Defense Advanced Research Projects Agency (DARPA), part of the U.S. Department of Defense. In 2015, Medicago also demonstrated that it could rapidly produce an anti-Ebola monoclonal antibody cocktail for the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services.
“The pace of our initial progress in COVID-19 is attributable to the capability of our plant-based platform, which is able to produce vaccine and antibody solutions to counteract this global public health threat. The ability to produce a candidate vaccine within 20 days after obtaining the gene is a critical differentiator for our proven technology. This technology enables scale-up at unprecedented speed to potentially combat COVID-19,” said Dr. Bruce Clark, CEO of Medicago.
Dr. Gary Kobinger, Professor in the Department of Microbiology and Infectious Diseases and the Director of the Infectious Disease Research Centre at Laval University, said “The collaborative efforts established between the research team at Laval University and Medicago have been very successful in developing unique antibodies against infectious diseases such as RSV and HMPV, and that experience gives us confidence for successful identification of therapeutic antibodies against SARS-CoV-2.”
Medicago’s first product, a seasonal recombinant quadrivalent VLP vaccine for active immunization against influenza, is currently under review by Health Canada following the completion of a robust safety and efficacy clinical program involving over 25,000 patients.
Notes to Editors:
Medicago’s unique plant-based platform
The company uses a proprietary plant-based technology to develop protein-based therapeutics. Unlike traditional vaccination development, Medicago does not use animal products or live viruses to create its products. Instead, it uses Virus-Like Particles (VLPs) that mimic the shape and dimensions of a virus, which allows the body to recognize them and create an immune response in a non-infectious way. Clinical trial data suggest that VLPs have a multi-modal mechanism of action that is different from that of inactivated vaccines, activating both arms of the immune system – antibody and cell-mediated responses.
Medicago’s proprietary technology is rapid, versatile, and scalable. As soon as the genetic sequence of a virus is made available, Medicago can develop a clinical-grade vaccine candidate in only a few weeks. Its recombinant technology allows the production of a vaccine that precisely matches the circulating strains, such as in the case of seasonal influenza. The technology is easily scalable, allowing the company to increase volume of production by simply increasing the number of plants it uses.
Product portfolio and pipeline
Medicago’s first product, a Recombinant Quadrivalent Virus-Like Particle (QVLP) seasonal flu vaccine, is presently under review by Health Canada. Vaccine candidates for pandemic flu, rotavirus and norovirus are being tested across pre-clinical and Phase II clinical trials. Medicago is also developing antibodies against hMPV, RSV and Opioids.
Facilities
Medicago is headquartered in Quebec City, Canada, and plans to produce COVID-19 vaccines and antibodies in its Quebec pilot plant to respond to the immediate short-term demand. The company also has a manufacturing facility in Durham, North Carolina (USA), which is currently dedicated to the production of vaccines and antibodies for its clinical trials and is expected to support the launch of the quadrivalent VLP influenza vaccine once it is approved. A new state-of-the-art manufacturing plant is under construction in Quebec City, which will be fully functional by 2023 and will have the capability to deliver up to 50 million doses of recombinant quadrivalent influenza vaccine per year.
About Medicago
Medicago is a biopharmaceutical company with more than 450 employees in Canada and the United States. Medicago’s mission is to improve global health outcomes by leveraging innovative plant-based technologies for rapid responses to emerging global health challenges. Medicago is committed to advancing therapeutics against life-threatening diseases worldwide.
For more information: www.medicago.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200312005345/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Perma-Pipe Accelerates Growth with New U.S. Northeast Facility Investment to serve Artificial Intelligence Data Center customers, Provides Middle East Operations’ Update and Concludes the Board’s Review of Strategic Alternatives19.3.2026 14:00:00 CET | Press release
Perma-Pipe International Holdings, Inc. (the “Company”) today announced a strategic expansion initiative focused on accelerating growth through entry into the high-demand U.S. Northeast region. The Company is positioning itself to capitalize on the rapidly expanding Artificial Intelligence (“AI”)-driven data center market in both the United States and international markets while continuing to reinforce its leadership in critical infrastructure solutions. As part of this growth strategy, Perma-Pipe will prioritize investments aimed at expanding its presence in the rapidly evolving AI data center sector. The initiative reflects the Company’s long-term commitment to supporting next-generation technology infrastructure and strengthening its position in the global energy, industrial, and infrastructure markets. Expansion in the U.S. Northeast President & Chief Executive Officer, Saleh Sagr said, “We are excited to announce the expansion of our operations with a new facility in the Northeast
Armis Launches First-of-Its-Kind Benchmark Report Warning of Critical Security Gaps in AI-Native Development19.3.2026 13:00:00 CET | Press release
Research reveals 100% of leading generative AI models fail to generate secure code for critical development scenarios Armis, the cyber exposure management & security company, is warning that the rapid enterprise adoption of AI-native development is outpacing critical security safeguards, leaving organizations exposed to systemic vulnerabilities. New research from Armis Labs’ Trusted Vibing Benchmark Report, which evaluates 18 leading generative AI models across 31 test scenarios, reveals a 100% failure rate in generating secure code. These vulnerabilities are most prevalent in high-risk areas like memory buffer overflows, design file uploads and authentication systems. Therefore, organizations should immediately implement AI-native application security controls to reduce risk. “The era of vibe coding is here, but speed should not come at the cost of security,” said Nadir Izrael, CTO and Co-Founder of Armis. “Our research finds that the worst offenders are the same ones selling security
Morocco’s FRMF Welcomes CAF Appeal Board as Upholding Rules, Stability of International Competitions19.3.2026 12:53:00 CET | Press release
Following the announcement by the CAF Appeal Board, the Royal Moroccan Football Federation (FRMF) welcomes the decision, which reaffirms the primacy of competition regulations and reinforces the conditions necessary for the proper conduct of international tournaments. From the outset, following the incidents that led to the interruption of the match, the FRMF maintained a clear and consistent position: the strict application of the governing regulations. The Federation’s approach was solely guided by this principle. Following its appeal, CAF has now confirmed that the applicable regulations were not properly enforced. Throughout the process, the FRMF acted in full compliance with all relevant legal and procedural frameworks, with a constant focus on upholding its rights and preserving the integrity of the competition. This decision provides clarity on the applicable framework and strengthens the consistency and credibility of international competitions, particularly within African foot
Hilton Announces Exclusive Agreement with YOTEL to Expand Global Footprint in Lifestyle Segment19.3.2026 12:00:00 CET | Press release
Independent, design-led YOTEL brand gains reach through Hilton’s global distribution platformHilton Honors members gain access to a sleek, contemporary new way to stayYOTEL will be the first independent brand as part of newly established Select by Hilton brand Hilton (NYSE: HLT) today announced an exclusive agreement with YOTEL that will provide guests yet another way to stay within the hospitality leader’s growing global portfolio. With highly efficient hotels in urban markets, YOTEL has pioneered ways to meet changing guest needs through stays that feature smart room design, and clever tech-enabled features. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318705963/en/ YOTEL Boston The franchise agreement with YOTEL expands Hilton’s network, filling a distinct customer need in the growing lifestyle segment in a manner consistent with its proven asset-light model. YOTEL will continue to independently manage and license it
Keenfolks Launches KEENFOLKS X_19.3.2026 12:00:00 CET | Press release
A Global AI-Native Marketing Infrastructure Network for Enterprise GrowthKeenfolks, the AI transformation partner behind marketing initiatives for brands including Coca-Cola, Diageo, Mars, Reckitt, Nestlé and Merck-MSD, today announced the launch of KEENFOLKS X_, a new global marketing network designed to operate on shared AI infrastructure The traditional holding company model that has shaped global marketing for decades is facing increasing pressure as capital markets, consolidation activity, and client demands point to a need for structural change. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260319751842/en/ Miguel Machado, CEO and Co-Founder, Keenfolks The marketing industry is searching for a new model. The question is no longer whether agencies need to change, but which ones were built for this shift from the start. Keenfolks, the Integrative AI® partner built natively for the Age of Intelligence, today announces th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom